Rachel Simmons
Adult Health · Baker, LANPI 1962753616
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $6,250 of the $10,404 with a category attached, or 60.1%. AbbVie accounts for 71.8% of it on its own, with 34 other manufacturers making up the rest. 2025 is the largest year on record at $6,899, 7.0 times the $983 reported in 2021. Among adult health clinicians in LA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 239 payments — averaging $43.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$7K
- Bayer$761
- Novo Nordisk$461
- Merz North America, Inc.$187
- Sanofi-aventis U.S. LLC$171
- Teva Pharmaceuticals USA, Inc.$166
- plus $1K from 29 others
What the payments were for
- Speaking & faculty fees$6,25060%
- Travel & lodging$2442%
- Food & beverage$3,91038%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 78 | $7,465 |
| Bayer | 31 | $761 |
| Novo Nordisk | 32 | $461 |
| Merz North America, Inc. | 5 | $187 |
| Sanofi-aventis U.S. LLC | 7 | $171 |
| Teva Pharmaceuticals USA, Inc. | 13 | $166 |
| Lilly USA, LLC | 10 | $162 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 6 | $119 |
| AstraZeneca | 6 | $95 |
| GSK | 5 | $82 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $62 |
| Abbott | 4 | $58 |
| Pfizer | 4 | $57 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $56 |
| Johnson & Johnson | 4 | $56 |
| Kowa Pharmaceuticals America, Inc. | 2 | $36 |
| Ardelyx, Inc. | 2 | $36 |
| Otsuka America Pharmaceutical, Inc. | 2 | $34 |
| Lundbeck LLC | 2 | $32 |
| Hologic Inc | 1 | $31 |
| Eisai Inc. | 2 | $31 |
| Amgen | 2 | $28 |
| Biohaven Pharmaceuticals, Inc. | 2 | $24 |
| Tolmar, Inc. | 1 | $21 |
| Daiichi Sankyo Inc. | 1 | $19 |
| Bausch Health US, LLC | 1 | $18 |
| Antares Pharma, Inc. | 1 | $18 |
| Embecta Corp. | 1 | $17 |
| Boehringer Ingelheim | 1 | $16 |
| Exact Sciences | 1 | $16 |
| Xeris Pharmaceuticals, Inc. | 1 | $15 |
| Boston Scientific | 1 | $15 |
| Merck | 1 | $13 |
| Supernus Pharmaceuticals, Inc. | 1 | $13 |
| Novartis | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$10,404 in reported general payments places this provider in the 90th percentile of 203 adult health providers in Louisiana.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 56 | $59,096 |
| JardianceEmpagliflozin | 41 | $27,796 |
| MounjaroTirzepatide | 21 | $22,456 |
| KerendiaFinerenone | 34 | $22,449 |
| VraylarCariprazine Hcl | 14 | $20,376 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 14 | $12,796 |
| LinzessLinaclotide | 14 | $12,789 |
| EntrestoSacubitril/Valsartan | 11 | $7,445 |
| FarxigaDapagliflozin Propanediol | 11 | $6,091 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 27 | $2,593 |
| Potassium Chloride | 43 | $2,240 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 45 | $1,343 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 32 | $1,070 |
| Gabapentin | 63 | $699 |
| Amlodipine Besylate | 149 | $678 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $461 | $59,09656 claims |
| AbbVieVraylar, Linzess | $7,465 | $33,16628 claims |
| Boehringer IngelheimJardiance | $16 | $27,79641 claims |
| Lilly USA, LLCMounjaro | $162 | $22,45621 claims |
| BayerKerendia | $761 | $22,44934 claims |
| GSKTrelegy Ellipta | $82 | $12,79614 claims |
| NovartisEntresto | $12 | $7,44511 claims |
| AstraZenecaFarxiga | $95 | $6,09111 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 203 adult health providers in Louisiana.
Other adult health in Baker
- Dustin LogueBaker$6K
- Joan SmithBaton Rouge$121K
- Fiona WinterbottomNew Orleans$51K
- Damika HarmonLake Charles$27K
- Jade CarrereHouma$23K
- Deborah SmithBaton Rouge$18K
- Tanisha SmithBaton Rouge$17K
- Eva Marina StaffordBaton Rouge$15K
- Dustin DenicolaBaton Rouge$14K
- Melissa LamaPonchatoula$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.